Medical Affairs


ViewRay's multi-center Clinical Cooperative Think Tank (C2T2)

Martin Fuss, MD, PhD, Assistant Professor, Radiation Oncology

C2T2's Executive Director, Martin Fuss, M.D., Ph.D.

ViewRay's C2T2 comprises clinicians from leading institutions around the world who are focused on evidence gathering to support MR-guided radiation therapy. This group includes:

  • Dana-Farber/Brigham and Women's Cancer Center in Boston
  • Henry Ford Cancer Institute, Detroit
  • Institut du Cancer de Montpellier, France
  • Institut Paoli Calmettes, Marseille, France
  • Loyola Center for Cancer Care and Research at Palos Health South Campus in Illinois
  • Moffitt Cancer Center in Tampa, Florida
  • Miami Cancer Institute, Baptist Health South Florida
  • National Cancer Center (NCC) in Tokyo, Japan
  • NewYork-Presbyterian Hospital
  • Orlando Health UF Health Cancer Center
  • Policlinico Agostino Gemelli, Universita Cattolica del Sacro Cuore, Gemelli ART in Rome, Italy
  • Seoul National University Hospital (SNUH) in Seoul, South Korea
  • Sylvester Comprehensive Cancer Center, UHealth - University of Miami Health System
  • University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center
  • University of Heidelberg, Germany
  • University of Wisconsin Carbone Cancer Center in Madison
  • VU University Medical Center in Amsterdam, Netherlands
  • Washington University and Siteman Cancer Center at Barnes-Jewish Hospital, St. Louis

Pancreatic Trial with MRI-guided RT

At the inaugural meeting of the C2T2 on September 23, 2017, participants formalized the group's first key initiative – a multi-center, prospective, single-arm clinical trial focused on locally advanced unresectable pancreatic cancer. Pancreatic cancer presents considerable radiation targeting challenges given the known limitations of conventional CT image guidance. The novel abilities provided by live MR guidance combined with daily online treatment adaptation have potentially enabled a new approach in pancreatic cancer therapy. Through this trial the group looks to explore new opportunities to improve survival and quality of life for this deadly disease.

To be informed of additional information about the Pancreatic Cancer Trial please sign up for our pancreatic trial updates here.

For the complete press release about the pancreatic cancer trial click to read the pancreatic cancer trial press release.




* Required

Subscribe to: Patient Information Newsletter
Copyright © 2018 ViewRay, Inc.. All rights reserved   -   Contact ViewRay